Marimastat

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Marimastat
Marimastat.svg
Clinical data
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
  • Development terminated?
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
PDB ligand
Chemical and physical data
Formula C15H29N3O5
Molar mass 331.408 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.[1][2]

Marimastat performed poorly in clinical trials,[3] and development was terminated.[citation needed]

See also[edit]

References[edit]

  1. ^ "Marimastat". National Cancer Institute. 
  2. ^ Millar, AW; Brown PD; Moore J; et al. (1998). "Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers". Br J Clin Pharmacol. 45 (1): 21–6. doi:10.1046/j.1365-2125.1998.00639.x. PMC 1873993Freely accessible. PMID 9489589. 
  3. ^ Sparano, JA (2004). "Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196". J Clin Oncol. 22 (23): 4683–90. doi:10.1200/JCO.2004.08.054. PMID 15570070.